Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia
- PMID: 20100951
- DOI: 10.1200/JCO.2009.26.7930
Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia
Comment on
-
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
